Vcare 2022 Annual Review
Published Time:
2023-01-20 17:39
Source:
I. Corporate Development and Infrastructure
① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd.
② CDMO Business Technology Center completed and operational.
③ Established new technology platform laboratories.
④ Built a new Innovative Drug Synthesis Technology Center.
II. Progress in Innovative Drug R&D Pipeline
① Vicagrel completed subject enrollment for key clinical trials.
② VC004 clinical trials advanced steadily with significant efficacy results.
③ VC005 obtained regulatory approval for multiple expanded indications.
④ Multiple preclinical projects progressed rapidly.
III. Drug R&D Services Sustained Growth
① CRO/CDMO service revenue exceeded RMB 300 million.
② New CRO/CDMO contracts signed valued at nearly RMB 500 million.
IV. Corporate Financing Status
① Successfully closed Series A financing totaling ~RMB 370 million.
② Completed Series B financing exceeding RMB 200 million.
V. Talent Development Initiatives
① Expanded workforce by 200+, reaching nearly 600 employees.
② Completed nearly 50 employee promotions.
③ Conducted ~80 employee training sessions.
④ Held management skills enhancement workshop.
⑤ Established strategic partnerships with multiple universities.
⑥ Launched 2nd employee equity incentive plan, covering ~120 employees.
VI. Awards & Honors
①Jiangsu Vcare Honored As: Nanjing Nurtured Unicorn Enterprise; Jiangsu 2022 Specialized, Refined, Unique, and Innovative SME; Top 30 in Nanjing High-Tech Zone Enterprise Innovation Index
②Nanjing Vcare Honored As: National Sci-Tech SME; Top 20 CRO Enterprises in China’s Pharmaceutical Industry
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn